Novartis and Arrowhead Pharmaceuticals have entered a substantial global licensing and collaboration agreement for Arrowhead’s preclinical siRNA therapy ARO-SNCA, targeting synucleinopathies including Parkinson’s disease. The partnership includes potential payments exceeding $2.2 billion, encompassing upfront, milestone, and commercial royalties. The deal leverages Arrowhead’s TRiM platform, which enables subcutaneous delivery of siRNA to the central nervous system, representing an innovative approach to targeting neurological diseases. Novartis’s investment further solidifies its commitment to RNAi therapeutics and neuroscience indications.